• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

H1 Launches Advanced Diversity and Clinical Trial Performance Insights

by Syed Hamza Sohail 03/13/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level diversity insights in addition to institution, provider, and patient diversity data within its Trial Landscape solution.

– Additionally, H1 has successfully onboarded its first customer – a top 20 pharmaceutical company – onto the H1 Data Network, a new solution that aggregates sponsor-contributed site and principal investigator (PI) performance data from clinical trial management systems (CTMS) to fuel transparency and clinical trial design.  

Healthcare Data Leader H1 Expands its Offerings With New Capabilities

Site feasibility and clinical operations teams at leading pharmaceutical companies use H1 Trial Landscape to discover diverse physician and patient populations and support more representative clinical trial participation. Trial Landscape is an exhaustive clinical trial intelligence repository, incorporating data from public and proprietary sources including over 10 million healthcare providers (HCPs) and over 420,000 clinical trials. It is the first solution of its kind to fully integrate diversity and inclusion insights at the site, HCP, patient, and now, the indication levels – accelerating site and PI research, validation, prioritization, diversity, and selection. 

By moving beyond the site level to include indication-level data, pharmaceutical companies can surface diversity insights on patients at a more granular level to design more inclusive clinical trials. For example, a user can now identify what percentage of breast cancer patients are African American in Georgia so, if they design a clinical trial in that state, they can recruit a representative population. With access to patient data this granular, clinical operations teams can better plan and design diverse clinical trials.

With the new H1 Data Network, pharmaceutical clients can contribute and share their CTMS data with other companies within the network and increase transparency within the industry. Unlike other networks, the H1 Data Network is open to pharmaceutical companies of all sizes, ensuring that midmarket and smaller companies have the same access to clinical trial performance data as big pharma. A top 20 pharmaceutical company is already contributing its data to the H1 Data Network, with many more planned in the near future. 

“Ensuring diversity in clinical trials is not just our mission; it’s a moral imperative and is essential for the development of effective and equitable healthcare solutions,” said Ariel Katz, CEO and co-founder of H1. “We continuously strive to improve our technology and our data to support this mission. These new capabilities are the latest advancements to equip pharmaceutical companies with the insights needed to meet this imperative by creating more diverse clinical trials and sharing that data back with the broader community.”

While the Food and Drug Administration (FDA) has encouraged clinical diversity over the past few decades, it is only now being enforced. The recently enacted 2023 Omnibus Spending Bill (Public Law 117-328) requires that diversity action plans be submitted for clinical trials used by the FDA to decide whether drugs are safe and effective. Other initiatives supporting clinical trial diversity include the National Institutes of Health’s recently released Minority Health and Health Disparities Strategic Plan 2021-2025, which focuses on improving diversity and inclusion in NIH-funded research with updated clinical trial policies and guidelines. With these laws, it will be up to pharmaceutical companies and researchers to engage and recruit diverse patient populations to take part in their trials.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Breast Cancer, cancer, Clinical Trial, Clinical Trials, Decentralized Clinical Trials, Diversity and Inclusion, FDA, global healthcare, H1, Health Disparities, Healthcare Data, NIH, Pharma

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |